In a post hoc analysis of pre-diabetic patients, treatment with Aphaia’s formulation for 6 weeks improved OGTT glucose level 2h post challenge from 8.72 ± 0.81 to 6.76 ± 1.13 mmol/L (n=12, p= 0.003); ...
MBX Biosciences stock surged on strong Phase 2 data for canvuparatide in hypoparathyroidism. Click here to find out why MBX ...
Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM ...
The science community has pushed back at the latest claims that acetaminophen (aka paracetamol) is a key factor in the ...
In this randomized trial, a home-based palliative educational app improved health-related quality of life (HRQoL) among ...
As a person firmly ensconced in middle age — 57 percent of the way through life, to be precise, if government actuarial tables hold — I have begun to notice certain things not working quite as well as ...
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies ...
China: Using a simple nasopharyngeal airway before painless gastrointestinal endoscopy can dramatically cut the risk of dangerous oxygen drops in obese outpatients, new research in Respiratory ...
Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback